BzATP (ammonium salt)

Please contact us at for specific academic pricing.

Background

BzATP (ammonium salt) is an agonist of the P2X receptors, exhibiting 5-30-fold higher potency at the P2X7 receptor than ATP. BzATP (ammonium salt) inhibits rat and mouse P2X7 receptors with EC50 values being 3.6 and 285 μM, respectively. However, BzATP (ammonium salt) is not selective for the P2X7 receptor as it can potently activate other P2X receptors, but without the marked superiority to ATP as an agonist. Activation of P2X7 receptors contributes to the proliferation and migration of certain types of tumor, including human glioma, and is involved in sepsis-induced intestinal barrier dysfunction. In addition, BzATP (ammonium salt) can also be used as a photoaffinity probe for exploring adenine nucleotide binding to ATPases.

1. Anderson CM, Nedergaard M. Emerging challenges of assigning P2X7 receptor function and immunoreactivity in neurons. Trends in Neurosciences, 2006, 29(5): 257-262.
2. Young MT, Pelegrin P, Surprenant A. Amino acid residues in the P2X7 receptor that mediate differential sensitivity to ATP and BzATP. Molecular Pharmacology, 2007, 71(1): 92-100.
3. Ji Z, Xie Y, Guan Y, et al. Involvement of P2X7 receptor in proliferation and migration of human glioma cells. BioMed Research International, 2018, 2018: 8591397.
4. Wu X, Ren J, Chen G, et al. Systemic blockade of P2X7 receptor protects against sepsis-induced intestinal barrier disruption. Scientific Reports, 2017, 7(1): 4364.
5. Williams N, Coleman PS. Exploring the adenine nucleotide binding sites on mitochondrial F1-ATPase with a new photoaffinity probe, 3'-O-(4-benzoyl)benzoyl adenosine 5'-triphosphate. Journal of Biological Chemistry, 1982, 257(6): 2834-2841.